The new, minimally invasive procedure developed by University at Buffalo researchers utilizes delivery of an antibody that targets and thus blocks the pro-inflammatory protein called tumor necrosis factor-alpha (TNF), specifically in the brain.
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources
American Academy of Pain Medicine (AAPM) is a nonprofit 501(c)(6) tax-exempt organization.